

Document Number:	TL12 (replaces TL2018/01)	Version Number:	2.0
Written by:	WADA LabEG	Approved by:	WADA LabEG*
Date:	31 January 2018	Effective Date:	31 January 2018

*The approval by the WADA Executive Committee is applicable only to Technical Letters issued after November 2019.

OSTARINE

The *World Anti-Doping Agency* wishes to draw the attention of the Laboratories to the structural similarities between aryl-propionamide based Selective Androgen Receptor Modulators (SARMs; prohibited under section “S1.2 Other Anabolic Agents” of the *Prohibited List*) and their non-prohibited analogs, and the need to include appropriate target compounds into the procedures to ensure the correct reporting of analytical findings for these *Prohibited Substances*.

Technical Letter TL07 (which replaces TL06/2016) addressed analytical findings for O-dephenyl-andarine, a *Metabolite* of andarine which may also be present in a *Sample* as a *Metabolite* of the permitted anti-androgen flutamide.

This TL12 pertains to the reporting of analytical results for another SARM, **ostarine** (also known as S-22 or Enobosarm).

Ostarine is excreted in urine mainly as the unmodified parent compound or as its glucuronide-conjugated phase-II *Metabolite*, whereas the abundance of the O-dephenyl-ostarine *Metabolite* is very low when compared to the parent drug. Furthermore, since O-dephenyl-ostarine could also be present in urine *Samples* as a contaminant/impurity and/or minor *Metabolite* of bicalutamide¹, this *Metabolite* shall not be considered as the sole criterion for the reporting of an *Adverse Analytical Finding* for ostarine.




Figure 1: Chemical structures of ostarine, bicalutamide and O-dephenyl-ostarine.

To correctly report findings for ostarine, *WADA* recommends the following:

“Reporting of *Adverse Analytical Findings* for ostarine shall be based on the detection of the parent compound (free form and/or glucuronide). Detection of ostarine and/or its glucuronidated conjugate constitutes unequivocal proof of ostarine *Use*, irrespective of the detection of bicalutamide and/or its *Metabolite(s)*”

Should you have any further questions, please do not hesitate to contact the *WADA* Science Department.

¹ Bicalutamide is a permitted, non-steroidal anti-androgenic medication of very similar chemical structure to ostarine (Figure 1), which is primarily used to treat prostate cancer. Ostarine is not a *Metabolite* of bicalutamide.